CLBT Q2 2025 Earnings Presentation

Page 1

Page 2

DISCLAIMER 13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. This presentation has been prepared by Cellebrite DI Ltd. (the “Company”) solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell securities, nor is it a solicitation of an offer to buy securities. This presentation is not directed at, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. Persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. In considering any performance information contained herein, you should bear in mind that past or projected performance is not necessarily indicative of future results, and there can be no assurance that any entity referenced herein will achieve comparable results or that illustrative returns, if any, will be met. Statements in this presentation are made as of the date this presentation is made unless stated otherwise, and the delivery of this presentation at any time shall under no circumstances create an implication that the information contained herein is correct as of any time after such date. Use of Non-GAAP Financial Measures This Presentation includes non-GAAP financial measures. Cellebrite believes that these non-GAAP measures are useful to investors for two principal reasons. First, Cellebrite believes these measures may assist investors in comparing performance over various reporting periods on a consistent basis by removing from operating results the impact of items that do not reflect core operating performance. Second, these measures are used by Cellebrite’s management to assess its performance. Cellebrite believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. These non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Other companies may calculate these non-GAAP financial measures differently, and therefore such financial measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this Presentation and is also available in our earnings release for the quarter on our website at investors.cellebrite.com. In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items. Forward-Looking Statements This presentation includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “p roject” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; Cellebrite’s dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite’s dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Page 3

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 3 * Based on internal research estimates MARKET LEADERSHIP Employees (6/30/25) ARR (6/30/25) Global Customers Serious crime legally-sanctioned investigations in 2024* Solution for digital forensic examiners $419M ~7,000 1.5M+ #1 1,216

Page 4

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 4OUR MISSION Protecting Communities, Businesses and Nations Innovating for a Safer World We empower more than 7,000 law enforcement, defense and intelligence, and enterprise customers to achieve their missions by helping them transform digital data into actionable intelligence.

Page 5

Page 6

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 6 o Static case closure rates o Skills gap of agency staff o Escalating officer attrition & burnout o Funding challenges THE RISING PUBLIC SAFETY GAP: POWERFUL MACRO TAILWINDS ↑ Digital Evidence ↑ Number of Cases ↑ Criminal Technical Sophistication ↑ Public Scrutiny Public Safety Gap

Page 7

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 7POWERFUL DEMAND DRIVERS * Real-Time Crime Index ** 2025 Cellebrite Industry Trends Survey → Constant crime rate and an increasing population* (leading to higher case load) → Digital evidence in 91% of crimes** → Increasing criminal technical sophistication → Static case closure rates → Skills gap of agency staff → Escalating officer attrition and burnout → Ever-increasing public scrutiny → Technology provider focus on data privacy → Artificial Intelligence use in Law Enforcement and Criminal Activity Three Major Challenges Data Volume & Complexity Inefficient Processes Ethics & Accountability Public Safety Gap

Page 8

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 8 AI-POWERED DIGITAL INVESTIGATION PLATFORM ANALYSIS & COLLABORATION SOLUTION ANALYZE & INVESTIGATE Analyze vast amounts of data to create actionable intelligence/collaborate MANAGE & CONTROL SOLUTION MANAGE & SAFEGUARD Manage & control of digital data, evidence and resources LAB & FIELD SOLUTION COLLECT & REVIEW Access & triage relevant evidence from the widest array of data source and types INSEYETS PATHFINDER GUARDIAN

Page 9

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 9 CELLEBRITE DIGITAL INVESTIGATION PLATFORM Removing Investigative Bottlenecks Leave no evidence behind From any service, over any device Inseyets Pathfinder Guardian Accelerate investigations securely Elevating efficiency while establishing a stronger chain-of-custody Build the complete picture Harnessing the power of AI to surface case insights Purpose-built, AI-powered, Cloud-ready

Page 10

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 10OUR CUSTOMERS CARE ABOUT TIME → Faster access to more devices. Extraction of more data. → Faster examinations. More actionable, high-value information. → Greater efficiency and productivity. → Faster analysis. A high-fidelity chain of custody. → Faster closure of more cases. Time-to-Data Time-to-Insights Time-to-Collaboration Time-to-Evidence Time-to-Justice Cellebrite Delivers

Page 11

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 11 IMAGE CLASSIFICATION & SIMILARITY TOPIC DETECTION TEXT TRANSLATION SPEECH TO TEXT IDENTITY RESOLUTION LEADING INVESTIGATIVE AI SINCE 2016 50K IMAGES AND VIDEO 250 CHAT PARTIES, MILLIONS OF MESSAGES OVER 30 COMMUNICATION APPS 120 HOURS OF VOICE 10 TO 15 SOCIAL ACCOUNTS Cellebrite AI CapabilitiesData Types

Page 12

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 12 72/1003000+ North American state and local accounts U.S. states50/50 Police departments in the 20 largest U.S. cities 20/20 Largest European police departments15/20* U.S. cabinet executive departments 15/15 North American federal accounts100+ Member E.U. national police 27/27 Of The Fortune 100 of Top 10 accounting firms10/10 of Top 10 pharma companies 8/10 of Top 10 U.S. commercial banks9/10 of Top 10 U.S. technology companies9/10 * 4 cities located in countries that Cellebrite does not actively participate commercially due to legal, ethical and business considerations. WORLD-CLASS CUSTOMER BASE PRIVATE SECTORPUBLIC SECTOR We’ve established our global footprint with meaningful room for expansion across our installed customer base

Page 13

Protecting Communities, Nations and Businesses Global Customers Law Enforcement and Justice Defense and Intelligence Enterprise and Service Providers Turn digital information into actionable intelligence to identify security risks, accelerate investigations and operations. Mobile Phones Computers and Workplace Applications Publicly Available Information 3rd Party Apps Cloud ServicesData Sources Customer Success Implementation, Training and Support Shared Architecture Secure and Compliant Scalable InteroperableUnified Data Model Industry-leading Solutions Inseyets PathfinderGuardian AI-POW ERED PLATFORM Corellium Falcon / Viper

Page 14

Page 15

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 15 → Privately held, based in Florida → ~85 People → Cellebrite to pay $170M in cash ($20M converted to equity at close) with additional $30M earn- out potential over 2 years → Deal expected to close by the end of Q325 → A leader in Arm-based Virtualization Software CELLEBRITE TO ACQUIRE CORELLIUM Rationale: TAM Expansion and Innovation → Supporting growth vectors within and beyond our core markets → Technology and expertise complements and augments CLBT Digital Investigation Portfolio → Broadens offerings for Defense and Intelligence → Extends reach into DevSecOps for secure mobile applications

Page 16

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 16SUPPORTS GROWTH VECTORS WITHIN AND BEYOND OUR CORE MARKETS A Safer & More Secure World Digital Investigation Solutions → Will position Cellebrite to efficiently accelerate its mobile vulnerability research → Already partnering to deliver an industry-first capability to enhance our digital forensics offerings by visualizing and interacting with virtual devices Defense & Intelligence Mobile App, Automotive and IoT Security → Will expand Cellebrite’s portfolio with powerful Mobile Vulnerability Research Solution for faster, more efficient vulnerability discovery, exploit validation and → Enabling development and security professionals to design the next generation of high-performance, secure mobile applications, IoT devices and automotive systems

Page 17

Page 18

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 18 * Non-GAAP Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non -GAAP metric and its most applicable GAAP measure. RESULTS HIGHLIGHTS 26% 21% 23% 26% TTM 6/24 TTM 6/25 ARR Growth Adj. EBITDA Margin Rule of X 49 47 Q2 24 $96M $113M +18% Total Revenue – Q2 25 Q2 24 $85M $103M +21% Subscription Revenue – Q2 25 JUNE 24 $346M $419M +21% ARR –JUNE 25 Q2 24 $22M 23% $28M 25% Adj. EBITDA & Adj. EBITDA %* – Q2 25

Page 19

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 19 $332 $346 $371 $396 $408 $419 Mar-24 Jun-24 Sep-24 Dec-24 Mar-25 Jun-25 SUSTAINABLE ARR GROWTH 23%25%26%26%27%% Total ARR Growth (Y/Y) ARR ($M) 21%

Page 20

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 20ARR COMPOSITION (FOR THE 12 -MONTH PERIOD ENDING JUNE 30, 2025) Inseyets Digital Forensics Guardian Evidence Management Pathfinder Investigative Analytics Guardian + Pathfinder Product Category Inseyets Customer Type Public Sector Private Sector Deployment Option On Premises Cloud

Page 21

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 21 JUNE-24 JUNE-25 Pathfinder & Guardian Families Inseyets Family JUNE-24 ARR GROWTH ($ IN MILLIONS) $345.9 $418.9 → June-25 ARR grew 21% → Gross revenue retention ~91% → Existing customer expansion fuels most of the ARR growth

Page 22

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 22EXPANDING WALLET SHARE WITH CUSTOMERS: Q225 SUCCESS $103M (Gross New ARR) State Public Safety Agency (USA) • Goal: Accelerate investigative workflows and improve operational efficiency • Deployed full Digital Investigative Platform (Inseyets, Guardian and Pathfinder) throughout its operations • New logo National Military (EMEA) • Goal: Improve situational awareness and decision making • Deploying Pathfinder to enable digitization and automation for unified, integrated intelligence operations • 50% increase in ARR National Police Agency (Asia-Pacific) • Goal: Standardize on advanced digital forensics across the nation to combat surge in major crimes • Nationwide upgrade to Inseyets with unlimited unlocks • 30% ARR expansion Inseyets Family Pathfinder & Guardian Families Inseyets Conversions1 1 Represents only the increase in ARR associated with new Inseyets pricing vs. legacy pricing Regional Police Agency (Asia-Pacific) • Goal: Fortify chain of custody and improve operational efficiency • Deployed Guardian * first-ever deployment in this country • 60% increase in ARR

Page 23

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 23ARR GROWTH BY GEOGRAPHY & ARR GEOGRAPHIC MIX ARR BY GEOGRAPHY ($ in millions) 54% 34% 12% ARR MIX BY GEOGRAPHY APAC JUNE-25 GROWTH: +21% EMEA JUNE-25 GROWTH: +17% AMERICAS JUNE-25 GROWTH: +24% $174 $119 $39 $183 $121 $42 $199 $126 $46 $215 $134 $47 $221 $137 $50 $226 $142 $51 Q124 Q224 Q324 Q424 Q125 Q124 Q224 Q324 Q424 Q125 Q124 Q224 Q324 Q424 Q125Q225 Q225 Q225

Page 24

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 24INVESTING IN OUR FUTURE $12.8 $15.6 $14.9 $17.0 $16.7 $16.9 86% 84% 86% 84% 84% 85% Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Cost of Goods Sold (Non-GAAP, $M) and Gross Margin (Non-GAAP, %) SUSTAIN HEALTHY SOFTWARE GROSS MARGIN PRUDENT INVESTMENT TO SUPPORT GROWTH Operating Expense (Non-GAAP, $M) and Operating Expense Margin (Non-GAAP, %) $60.9 $60.3 $62.5 $65.1 $68.8 $70.2 68% 63% 58% 60% 64% 62% Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non -GAAP metric and its most applicable GAAP measure.

Page 25

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 25CASH POSITION $87.6 $189.5 $191.7 $90.5 $179.2 $66.8 $67.6 $138.4 $241.6 $232.6 $51.3 $74.7 $153.7 $177.8 $146.1 2022 2023 2024 Q125 Q225 Cash & Cash Equivalents Short-Term & Long-Term Marketable Securities Deposits $205.7 $331.8 $483.8 $557.8 CASH & INVESTMENTS ($ in millions) Note: Numbers may not total due to rounding $509.8

Page 26

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 26FREE CASH FLOW AND FREE CASH FLOW MARGIN 66% GROWTH IN FREE CASH FLOW DRIVES FREE CASH FLOW MARGIN TO 34% $28.1 $41.6 $8.5 $12.4 $90.7 $39.8 $62.8 $18.5 $29.0 $150.1 Q323 Q423 Q124 Q224 Prior TTM Q324 Q424 Q125 Q225 TTM 1 Defined as cash flow provided by operations less capital expenditures 34.4% 25.0% Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non-GAAP metric and its most applicable GAAP measure. $ in millions FCF and FCF margin have increased each quarter for the TTM ended 6/30/25

Page 27

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 27WEIGHTED AVERAGE SHARES OUTSTANDING (BASIC) 195.7 196.7 198.9 208.7 233.0 237.2 1.0 2.2 2.4 2.5 0.7 3.1 7.4 22.0 3.5 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Opening Balance Company Equity Plans Merger-Related Equity Instruments Majority of merger-related instruments issued in FY24-Q3 Expecting WASO to increase by ~1.2M shares each quarter due to the reduced quantity of exercisable options and other equity programs Exercisable equity contracted from 9.9M to 3.9M over the last 12 months Shares in millions 196.7 198.9 208.7 233.2 237.2 240.3

Page 28

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 28FINANCIAL FORECAST 2024A Q3 ‘25 EXPECTATIONS (AS OF 08/14/25) FY ‘25 EXPECTATIONS (AS OF 08/14/25) ARR $396M $435M - $445M $460M - $475M ARR Growth (y/y) +25% +17% - +20% +16% - +20% Revenue $401M $121M - $126M $465M - $475M Revenue Growth (y/y) +23% +13% - +18% +16% - +18% Adjusted EBITDA* $99.4M $31M - $34M $118M - $123M Adjusted EBITDA Margin* 24.8% 26% - 27% 25% - 26% * Non-GAAP Note: non-GAAP metrics and key performance indicators defined in the appendix along with a reconciliation between the non -GAAP metric and its most applicable GAAP measure

Page 29

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 29 SUMMARY Protecting Communities, Businesses and Nations → A healthy market with powerful tailwinds → Disruptive technology elevates productivity and efficiency → End-to-end platform for the public and private sector → AI-powered and cloud-ready solutions → Increasing wallet share with diverse, global customer base → Rule of X baseline performance range between 45-to-50 → Firepower accelerate innovation and TAM expansion

Page 30

Page 31

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 31 This presentation includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating income margin, non-GAAP net income, non-GAAP EPS, adjusted EDITDA and adjusted EBITDA margin, free cash flow and free cash flow margin is helpful to investors. These measures, which the Company refers to as our non-GAAP financial measures, are not prepared in accordance with GAAP. The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance fr om period to period, and offer investors and management greater visibility to the underlying performance of its business. Mainly: • Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses; • Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the ac quisition, and acquisition-related expenses are unrelated to current operations and neither are comparable to the prior period nor predictive of future results; • To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income; • Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performan ce and make period-to-period comparisons more challenging; and • Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company’s current operations and affect financial income. Free cash flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment and capitalized internal-use software. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or u sed in our operations that, after the investments in property and equipment, can be used for strategic initiatives. Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating ou r own operating results over different periods of time. The non - GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternativ es to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non- GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our in dustry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share -based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compen sation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisi tion-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimat e movements in foreign currencies. A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table incl uded at the end of this presentation, which is also available on our website at https://investors.cellebrite.com. In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking Adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fai r value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items. USE OF NON-GAAP FINANCIAL INFORMATION

Page 32

Page 33

Page 34

Page 35

Page 36

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 36DEFINITIONS → Annual Recurring Revenue Annual recurring revenue (ARR) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. → Subscription Revenue Is defined as revenue from recurring, term-based license contracts and ongoing services related to core offerings. Subscription revenue is recognized ratably over the subscription term with a portion of revenue, related to the term-based license, recognized upfront.

Page 37

Page 38

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 381. COMPLEXITY & VOLUME Sources: (1) Policing: A Journal of Policy and Practice, Dec. 16, 2022 (2) Cellebrite 2025 Industry Trends Report 90% Of crimes have a digital component1 66% % of locked phones that reach the lab2 77% % of examiners who believe they lack the tools they need2 of agency managers have noted a 76% growth in digital data from devices over the past three years2 +76%

Page 39

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 392. INEFFICIENT PROCESSES 3 to 4 WEEKS Examiners consistently report 3 to 4 weeks of digital forensic examination backlogs3 This increasing workload highlights the need for optimized workflows to keep pace with growing demands3 71% Of Investigators conduct daily online searches – a process that is neither quick nor efficient3 80% % of investigators report lacking the necessary tools to easily review digital data, hindering their ability to efficiently analyze evidence.2 HOURS per case 69

Page 40

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 403. ETHICS & ACCOUNTABILITY 48% Of examiners have advanced or extensive formal training , highlighting a pressing need for cutting- edge solutions and resources.3 60% of investigators rely on outdated methods, such as USB sticks, to share forensic data within their agencies.3 68% Of investigative teams do not have time to review and analyte all digital data3 30+ Passed police reform and oversight bills since 20204 U.S. States

Page 41

13 August 2025 www.cellebrite.com www.cellebrite.com © 2025 Cellebrite DI Ltd. 41 agree AI can accelerate large-volume data analysis3 AI & THE CLOUD agree that AI reduces human error and prioritizes evidence 3 acknowledge AI’s investigative improvements3

Slides